A Clinician's Guide to Co-occurring ADHD among Adolescent Substance Users: Comorbidity, Neurodevelopmental Risk, and Evidence-based Treatment Options.
A Clinician's Guide to Co-occurring ADHD among Adolescent Substance Users: Comorbidity, Neurodevelopmental Risk, and Evidence-based Treatment Options.
复制标题
青少年药物使用者并发 ADHD 的临床医生指南：合并症、神经发育风险和循证治疗选择。
DOI：
10.1080/1067828x.2017.1305930
复制
发表时间：
2017
影响因子：
0.6
通讯作者：
Levin,FrancesR
中科院分区：
文献类型：
--
作者：
Hogue,Aaron;Evans,StevenW;Levin,FrancesR
本文介绍了神经发育和临床考虑治疗青少年同时发生的注意缺陷多动障碍（ADHD）和青少年物质使用（ASU）在门诊设置。我们首先描述了ADHD和ASU常见的神经生物学损伤，包括与品行障碍的共病，引起了倍增的发展风险。然后，我们提出了两个基于证据的选择，以针对ADHD相关的问题，在ASU治疗。药物整合干预utilize家庭ADHD心理教育，以促进决策有关ADHD药物和药物管理整合到行为服务。临床为基础的学术培训干预利用家庭干预，以改善家庭学术环境和提高组织能力。最后，我们提出了ADHD评估和干预顺序的建议。
This article introduces neurodevelopmental and clinical considerations for treating adolescents with co-occurring attention deficit hyperactivity disorder (ADHD) and adolescent substance use (ASU) in outpatient settings. We first describe neurobiological impairments common to ADHD and ASU, including comorbidity with conduct disorder, that evoke a profile of multiplicative developmental risk. We then present two evidence-based options for targeting ADHD-related problems during ASU treatment.Medication integration interventionsutilize family ADHD psychoeducation to prompt decision making about ADHD medication and integrate medication management into behavioral services. Clinic-basedacademic training interventionsutilize family interventions to improve the home academic environment and boost organization skills. We conclude with recommendations for ADHD assessment and intervention sequencing.